Effect of Increased Daily Water Intake in Patients With Hyperuricemia
NCT06315543 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88
Last updated 2024-12-27
Summary
The purpose of this study is to explore the clinical effect of reducing uric acid by drinking water, and provide scientific evidence and clinical guidance for reducing uric acid by drinking water. The study design was a multicenter, prospective, randomized controlled clinical trial with a total of 88 participants (Group A n=44; Group B n=44). 1. Inclusion criteria: patients with hyperuricemia (fasting uric acid between 420-540μmol/L twice on different days and no drug treatment); Aged 18-65 years; Less than 1500mL of daily water intake recommended by the minimum dietary guidelines (assessed by dietary review combined with water diaries); Fully informed consent. Sign informed consent. 2. Exclusion criteria: Patients with heart, liver and kidney insufficiency; Patients with severe or uncontrollable organic diseases that may interfere with the study parameters (such as tumors, cardiovascular, pulmonary and digestive diseases, hypertension, hyperlipidemia, hyperglycemia, thyroid diseases) or psychiatric disorders that affect eating behavior (such as primary polydipsia, bulimia nervosa, Psychiatric disorders, etc.); Patients with secondary hyperuricemia caused by other diseases; Patients who have taken any drug that causes changes in uric acid within five half-lives of the drug; Receiving treatment that can change the assessment of hydration status in the study (taking diuretics, glucocorticoids, or treatments that interfere with metabolism); Those who have gastrointestinal discomfort or a history of gastrointestinal surgery after drinking water, and other patients who are not suitable to drink too much water. A total of 88 subjects were included according to the exclusion criteria. The subjects were divided into two groups: Group A adequate drinking water intervention group (drinking an additional 1650mL of water per day (3 bottles of 550mL bottled water) on the basis of the original drinking water volume); Group B constant drinking water observation group (maintaining the original drinking water volume). During the 2-week observation period, the effects of sufficient drinking water on blood uric acid, urine osmotic pressure and other indicators were evaluated, and the effectiveness of sufficient drinking water in reducing blood uric acid was determined, and the applicable population was explored.
Observation items and detection time: 1. During the screening period, the following data were collected: age, nationality, place of residence, education, occupation, height, weight, waist circumference, disease history, drug use history, drinking, smoking, normal water intake, urine volume, urine color and uric acid value. 2. Pre-test data: drinking water, urination, diet, psychological investigation, blood uric acid, blood biochemistry, routine blood routine, urine routine, uric acid, urine osmotic pressure, systolic blood pressure, diastolic blood pressure, heart rate, frequency of gout attack, whether to take uric-lowering drugs, whether to take other drugs that affect uric acid. 3. After the test: Fasting blood uric acid was monitored on the 2nd, 4th, 6th, 8th, 10th and 14th day respectively; Urge patients to record water diary and urination diary every day. At the end of the experiment, blood uric acid, blood biochemistry, blood routine, urine routine, urine uric acid, urine osmotic pressure, systolic blood pressure, diastolic blood pressure and heart rate were tested again. Safety assessment indicators: edema, gastrointestinal discomfort, electrolytes, blood pressure, heart rate.
Conditions
- Hyperuricemia
Interventions
- DIETARY_SUPPLEMENT
-
Drink water
Increase drinking water by 1650mL per day (3 bottles of 550mL bottled water)
Sponsors & Collaborators
-
Xijing Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-23
- Primary Completion
- 2024-11-27
- Completion
- 2024-11-27
Countries
- China
Study Locations
More Related Trials
-
Effects of Barley Green in Patients With Hyperuricemia
NCT04438486 ·Status: UNKNOWN ·Phase: NA
-
Prebiotics and the Management of Hyperuricemia
NCT06420401 ·Status: RECRUITING ·Phase: NA
-
The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia
NCT06084585 ·Status: RECRUITING ·Phase: NA
-
Research and Development of a New Technology for Detection of Abnormal Excretion of Intestinal Uric Acid Involved in the Incidence of Gout
NCT04953533 ·Status: UNKNOWN
-
A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.
NCT00208000 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Prebiotics on Hyperuricemia
NCT05385003 ·Status: UNKNOWN ·Phase: NA
-
Prednisone for Heart Failure Patients With Hyperuricemia
NCT02129764 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia
NCT02502565 ·Status: UNKNOWN
-
Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers
NCT05226013 ·Status: UNKNOWN ·Phase: PHASE1
-
The Relationship Among, Serum Uric Acid, Left Ventricular Hypertrophy and Metabolic Syndrome
NCT03473951 ·Status: UNKNOWN
-
Screening and Management of Hyperuricemia in Patients with Chronic Medical Diseases in Assiut University Hospital
NCT06586229 ·Status: NOT_YET_RECRUITING
-
An Innovative Chinese Herbal Formula for the Treatment of Gout
NCT05499312 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia
NCT05302388 ·Status: COMPLETED ·Phase: PHASE1
-
Hyperuricemia and Diabetic Nephropathy
NCT04799925 ·Status: UNKNOWN
-
Prednisone for Heart Failure Patients With Hyperuricemia
NCT00919243 ·Status: COMPLETED ·Phase: PHASE4
-
The Effects of a Probiotic Food Supplement in Hyperuricaemia
NCT07141888 ·Status: RECRUITING ·Phase: NA
-
The Diet Gout Trial
NCT03569020 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia
NCT04638543 ·Status: COMPLETED ·Phase: PHASE2
-
Single Dose Study of SHR4640 in Healthy Subjects
NCT02815839 ·Status: COMPLETED ·Phase: PHASE1
-
Gout Dose Response Study
NCT00955981 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients
NCT02290210 ·Status: COMPLETED ·Phase: PHASE2
-
Prevalence of Hyperuricemia in Pakistan
NCT03473444 ·Status: UNKNOWN
-
GOS and the Management of Hyperuricemia
NCT06630377 ·Status: RECRUITING ·Phase: NA
-
Effect of Allopurinol Treatment on Insulin Resistance
NCT02008968 ·Status: UNKNOWN ·Phase: NA
-
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
NCT03934099 ·Status: COMPLETED ·Phase: PHASE2